SCHEMBL5398394

SCHEMBL5398394

Cn1c(=O)c2c(-c3cccc(C(=O)O)c3)n(Cc3cccc4ccccc34)nc2n(Cc2ccccc2)c1=O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
HPGD P15428 3/20 0.43
DPP4 P27487 1/20 0.42
ADORA2B P29275 1/20 0.41
MAPK8 P45983 1/20 0.41
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
NPC1 O15118 1/20 0.40
MMP13 P45452 1/20 0.40
SLC22A8 Q8TCC7 1/20 0.40
EIF4EBP1 Q13541 2/20 0.40
PPARG P37231 1/20 0.40
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 2/20 0.39
MAPT P10636 2/20 0.39
HSD17B10 Q99714 2/20 0.39
LMNA P02545 2/20 0.39
CYP3A4 P08684 1/20 0.39
SLC22A12 Q96S37 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5411110 0.95 MEN1 (0.47) MEN1KMT2AHPGDDPP4ADORA2B
SCHEMBL5410909 0.95 MEN1 (0.47) MEN1KMT2ADPP4MAPK8SMN1; SMN2
SCHEMBL5418106 0.94 MAPT (0.47) MEN1KMT2AHPGDDPP4ADORA2B
SCHEMBL5398717 0.94 MEN1 (0.45) MEN1KMT2ADPP4MAPT
SCHEMBL5402322 0.93 MEN1 (0.45) MEN1KMT2ASMN1; SMN2ALDH1A1LMNA
SCHEMBL5410867 0.93 NPC1 (0.46) MEN1KMT2ADPP4ADORA2BRAB9A
SCHEMBL5404381 0.92 MEN1 (0.42) MEN1KMT2AHPGDADORA2BSMN1; SMN2
SCHEMBL5402833 0.92 AGTR1 (0.45) MEN1KMT2AMAPK8PPARG
SCHEMBL5415311 0.92 KMT2A (0.43) MEN1KMT2AHPGDDPP4ADORA2B
SCHEMBL5395755 0.92 TSHR (0.46) MEN1KMT2ADPP4ADORA2BRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285558-B2 Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections ASTRAZENECA AB (SE) 2007-10-23 US disclosed
US-20040254183-A1 Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections ASTRAZENECA AB (SE) 2004-12-16 US disclosed
EP-1412355-A1 NEW PYRAZOLO(3,4-D)PYRIMIDINES INHIBITING H. PYLORI INFECTIONS AstraZeneca AB (SE) 2004-04-28 EP disclosed
WO-2003002567-A1 NEW PYRAZOLO[3,4-D]PYRIMIDINES INHIBITING H. PYLORI INFECTIONS ASTRAZENECA AB (SE) 2003-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254183-A1 Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections DPYD, HPGDS, PGC MEN1 4216/4885KMT2A 3837/4885HPGD 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.